Publications by authors named "M Agirbasli"

Hyperglycaemia, hyperlipidaemia, hypertension and obesity are the main risk factors affecting the development and prognosis of ischaemic heart disease, which is still an important cause of death today. In our study, male Sprague-Dawley rats were fed either a standard diet (SD) or a high fat and high carbohydrate diet (HF-HCD) for 8 weeks and streptozotocin (STZ) was injected at the seventh week of the feeding period. In one set of rats, a mixture of a prebiotic and probiotics (synbiotic, SYN) was administered by gavage starting from the beginning of the feeding period.

View Article and Find Full Text PDF

Objective: The purpose of this study is to evaluate whether hepatosteatosis is associated with lung cancer in patients undergoing lung nodule biopsy.

Methods: 359 patients (248 males, 69.1%) who underwent lung biopsy between the years 2016 and 2022 were included in this retrospective study.

View Article and Find Full Text PDF

Objectives: The aim of the study was to investigate serum plasminogen activator inhibitor-1 (PAI-1) levels of patients with Parkinson's disease (PD) and their relationship with clinical findings and treatment of disease.

Methods: The study included 125 PD patients and 48 healthy controls. Patients have been taking effective dopaminergic treatment regularly.

View Article and Find Full Text PDF

Objective: To investigate high-density lipoprotein cholesterol (HDL-C) levels in children with COVID-19.

Study Design: Descriptive study. Place and Duration of the Study: Goztepe Professor Suleyman Yalcin City Hospital, Istanbul, Turkiye, between 2020 and 2022.

View Article and Find Full Text PDF
Article Synopsis
  • TM5614, an inhibitor targeting plasminogen activator inhibitor (PAI)-1, showed potential benefits by reducing thrombosis, inflammation, and fibrosis in mouse models.
  • In a trial with 26 Japanese COVID-19 patients, TM5614 was administered daily, resulting in all patients being discharged without significant side effects.
  • A larger, randomized trial planned for 100 patients enrolled only 75, showing TM5614's effects on oxygenation and days of oxygen use were minimal compared to placebo, indicating the need for further research on its efficacy for treating COVID-19 pneumonia.
View Article and Find Full Text PDF